GR3020715T3 - Xanthine compounds - Google Patents

Xanthine compounds

Info

Publication number
GR3020715T3
GR3020715T3 GR960402079T GR960402079T GR3020715T3 GR 3020715 T3 GR3020715 T3 GR 3020715T3 GR 960402079 T GR960402079 T GR 960402079T GR 960402079 T GR960402079 T GR 960402079T GR 3020715 T3 GR3020715 T3 GR 3020715T3
Authority
GR
Greece
Prior art keywords
chem
effect
independently represents
renal
lower alkyl
Prior art date
Application number
GR960402079T
Other languages
English (en)
Inventor
Fumio Suzuki
Junichi Shimada
Akio Ishii
Tetsuji Ohno
Akira Karasawa
Kazuhiro Kubo
Hiromi Nonaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of GR3020715T3 publication Critical patent/GR3020715T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/20—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
GR960402079T 1989-09-01 1996-08-02 Xanthine compounds GR3020715T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP22664289 1989-09-01

Publications (1)

Publication Number Publication Date
GR3020715T3 true GR3020715T3 (en) 1996-11-30

Family

ID=16848383

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960402079T GR3020715T3 (en) 1989-09-01 1996-08-02 Xanthine compounds

Country Status (11)

Country Link
EP (1) EP0415456B1 (el)
JP (1) JPH06102662B2 (el)
AT (1) ATE139778T1 (el)
BR (1) BR1100762A (el)
CA (1) CA2024381C (el)
CY (1) CY2069B1 (el)
DE (1) DE69027562T2 (el)
DK (1) DK0415456T3 (el)
ES (1) ES2091212T3 (el)
GR (1) GR3020715T3 (el)
HK (1) HK1000600A1 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz
EP0556778A3 (en) * 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
TW252044B (el) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
WO1995031460A1 (fr) * 1994-05-17 1995-11-23 Kyowa Hakko Kogyo Co., Ltd. Procede pour produire un derive de xanthine
AU4527896A (en) 1994-12-13 1996-07-03 Euro-Celtique S.A. Aryl thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
ATE247655T1 (de) 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
WO1998057644A1 (fr) * 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Agent de prevention et remede contre la nephropathie induite par les medicaments
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
US6521656B1 (en) * 1998-06-01 2003-02-18 Fujisawa Pharmaceutical Co., Ltd. Remedies for male sterility
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
EP1775297A3 (en) 1999-11-12 2008-12-03 Biogen Idec MA Inc. Adenosine receptor antagonists and methods of making and using the same
CZ20021614A3 (cs) * 1999-11-12 2002-07-17 Biogen, Inc. Polycykloalkylpuriny jako antagonisty adenosinového receptoru
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
YU42903A (sh) 2000-12-01 2006-05-25 Biogen Inc. Kondenzovani derivati purina kao antagonisti a1 receptora adenozina
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
EP1513848A4 (en) * 2002-06-12 2005-11-09 Biogen Idec Inc METHOD FOR TREATING ISCHEMIA REPERFUSION INJURIES WITH ADENOSINE RECEPTOR ANTAGONISTS
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
JP2006515316A (ja) * 2003-05-06 2006-05-25 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストであるキサンチン誘導体
CN1894250B (zh) * 2003-08-25 2010-06-09 PGx健康有限责任公司 取代的8-杂芳基黄嘌呤
WO2007069675A1 (ja) 2005-12-14 2007-06-21 Kyowa Hakko Kogyo Co., Ltd. キサンチン誘導体の易吸収性経口製剤
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1245969B (de) * 1967-08-03 VEB Arzneimittelwerk Dresden, Radebeul Verfahren zur Herstellung von Xanthinderivaten
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
GB8618931D0 (en) * 1986-08-02 1986-09-10 Euro Celtique Sa 6-thioxanthines
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung

Also Published As

Publication number Publication date
DE69027562T2 (de) 1997-02-20
CA2024381C (en) 1997-01-07
DK0415456T3 (da) 1996-07-29
EP0415456A3 (en) 1991-05-29
BR1100762A (pt) 2000-03-14
CA2024381A1 (en) 1991-03-02
DE69027562D1 (de) 1996-08-01
JPH06102662B2 (ja) 1994-12-14
JPH03173889A (ja) 1991-07-29
EP0415456B1 (en) 1996-06-26
HK1000600A1 (en) 1998-04-09
ES2091212T3 (es) 1996-11-01
ATE139778T1 (de) 1996-07-15
EP0415456A2 (en) 1991-03-06
CY2069B1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
CY2069B1 (en) Xanthine compounds
GR3020369T3 (en) Xanthine derivatives
EP0031567A3 (en) Tetrapeptidesemicarbazide derivatives and their production and use
PL263885A1 (en) Method of obtaining novel derivatives of dihydrobenzofurane and chromate carbonamide
PL249964A1 (en) Process for preparing novel derivatives of 7-//z/-2-/2-aminothiazolyl-4/-2-oxyiminoacetamide/-3-cephemo-4-carboxylic acid
ATE71944T1 (de) Thiazolderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
GR3002692T3 (en) Benzoxazine derivatives and processes for preparation thereof
HUT54362A (en) Process for producing cumarin derivatives and pharmaceutical compositions containing them
DE3477380D1 (en) Novel benzothiazepine derivatives, processes for preparing the same and pharmaceutical compositions
ES2003086A6 (es) Procedimiento de obtencion de tienoquinolicinsulfonamidas
ATE30724T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten.
DE68900990D1 (en) Thioformamid-derivate.
GR3007219T3 (el)
EP0347880A3 (en) Imidazo[2,1-b]benzothiazole compounds and antiulcer compositions containing the same
FI883507A (fi) Naftotiazepinderivat och deras framstaellning.
AU4370489A (en) The use of oxidized polyamines, especially nn'-bis-(3- propionaldehyde)-1-4-diaminobutane (sperminedialdehyde) as immunosuppressive agents
PH25608A (en) 3-amino-tetrahydro-isoquinoline
MY101746A (en) 1,5-benzothiazepine derivatives, a process for preparing the same, pharmaceutical compositions as well as the use thereof.
MX9701841A (es) Derivados aminoheterociclicos como agentes antitromboticos o anticoagulantes.